Top 5 Copay Program Fallacies

Top 5 Copay Program Fallacies

Your copay program can have a huge impact on patients, affecting not only their wallets, but also their overall health. With that in mind, it is important to not be misled by common misconceptions that arise in designing or managing your copay program—they can hinder your performance, creating a ripple effect on your business and your patients.

Identifying these bad practices and changing course is often the best to way to determine what approaches work for your company, and to develop best practices for the future.

There are many common misconceptions associated with designing or managing your copay program. Don’t be fooled by them, as they are likely hindering your performance.

To help identify the “good” it’s worthwhile sometimes to understand the “bad,” otherwise how will you know what “good” practices really are?

Here is a list of our top five fallacies in the copay program world.



Remember to continuously reevaluate your copay program to see if you’ve fallen into one (or more) of these traps. This self-assessment will help keep you out of these practices.

Do you have questions? Contact us.

 The Truveris Patient Access Services team is committed to providing insights and analysis to help pharmaceutical brand teams make the most informed decisions. This post was originally published last year, but we’ve updated it to reflect the most current statistics and information from across the prescription drug landscape.


Topics: Trends, Insights & Analysis, Pharmaceutical Manufacturers, Copay Programs

Posted by

Fendi Liu

Fendi Liu is a member of Truveris’ Life Sciences Team. In her role as Operations Manager, Fendi oversees the operations of patient access programs at Truveris. Fendi has a Bachelor’s Degree in Business Administration and International Business & Marketing from The George Washington University.